Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Mirum Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Mirum Pharmaceuticals, Inc.’s stock price such as:

• Mirum Pharmaceuticals, Inc.’s current stock price and volume
• Why Mirum Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for MIRM from analysts
• MIRM’s stock price momentum as measured by its relative strength

About Mirum Pharmaceuticals, Inc. (MIRM)

Before we jump into Mirum Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS. The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.

Want to learn more about Mirum Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of May 15, 2026, 10:27 AM, CST, Mirum Pharmaceuticals, Inc.’s stock price was $109.110.

Mirum Pharmaceuticals, Inc. is down 2.05% from its previous closing price of $111.390.

During the last market session, Mirum Pharmaceuticals, Inc.’s stock traded between $107.170 and $110.250. Currently, there are approximately 58.85 million shares outstanding for Mirum Pharmaceuticals, Inc..

Mirum Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Mirum Pharmaceuticals, Inc. Stock Price History

Mirum Pharmaceuticals, Inc.’s (MIRM) price is currently up 12.13% so far this month.

During the month of May, Mirum Pharmaceuticals, Inc.’s stock price has reached a high of $114.990 and a low of $88.336.

Over the last year, Mirum Pharmaceuticals, Inc. has hit prices as high as $114.990 and as low as $42.890. Year to date, Mirum Pharmaceuticals, Inc.’s stock is up 38.13%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Mirum Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 14, 2026, there were 0 analysts who downgraded Mirum Pharmaceuticals, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Mirum Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Mirum Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Mirum Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Mirum Pharmaceuticals, Inc. (MIRM) by visiting AAII Stock Evaluator.

Relative Price Strength of Mirum Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 14, 2026, Mirum Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 15.80%, which translates to a Momentum Score of 87 and is considered to be Very Strong.

Want to learn more about how Mirum Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Mirum Pharmaceuticals, Inc. Stock Price: Bottom Line

As of May 15, 2026, Mirum Pharmaceuticals, Inc.’s stock price is $109.110, which is down 2.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Mirum Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.